Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
Status:
Completed
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
The primary goal of this Phase 1 study is to characterize the safety and tolerability of
MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to
patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the
anti-tumor activity of MGD007 will also be assessed.